Stifel GMP analyst Andrew Partheniou upgraded Supreme Cannabis to Buy from Hold with a price target of C$0.20, up from C$0.15, upon resuming coverage following the company’s equity financing. The company has “regained its footing” in the recreational market and now has a balance sheet with flexibility to pursue strategic growth initiatives along with “a right-sized operating profile” that should allow for sustainable profitability, the analyst tells investors.